Dyne Therapeutics (NASDAQ:DYN) Downgraded by StockNews.com to Sell

Dyne Therapeutics (NASDAQ:DYN) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Saturday.

Other equities research analysts also recently issued research reports about the stock. Chardan Capital boosted their price objective on shares of Dyne Therapeutics from $31.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, May 21st. JPMorgan Chase & Co. boosted their price objective on shares of Dyne Therapeutics from $39.00 to $43.00 and gave the company an “overweight” rating in a research report on Tuesday, July 9th. Stifel Nicolaus upped their target price on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, August 16th. HC Wainwright upped their target price on shares of Dyne Therapeutics from $48.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, August 13th. Finally, Piper Sandler upped their target price on shares of Dyne Therapeutics from $43.00 to $53.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.60.

Dyne Therapeutics Trading Up 2.3 %

Shares of DYN opened at $46.53 on Friday. The firm has a market cap of $4.07 billion, a PE ratio of -11.72 and a beta of 1.07. The firm has a fifty day simple moving average of $40.03 and a two-hundred day simple moving average of $31.54. Dyne Therapeutics has a 1-year low of $6.40 and a 1-year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.02. As a group, research analysts forecast that Dyne Therapeutics will post -3 EPS for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, SVP Richard William Scalzo sold 1,590 shares of the stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $30.23, for a total transaction of $48,065.70. Following the completion of the transaction, the senior vice president now owns 115,105 shares of the company’s stock, valued at approximately $3,479,624.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Oxana Beskrovnaya sold 2,136 shares of the company’s stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $31.34, for a total transaction of $66,942.24. Following the sale, the insider now directly owns 147,511 shares in the company, valued at approximately $4,622,994.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Richard William Scalzo sold 1,590 shares of the company’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $30.23, for a total transaction of $48,065.70. Following the sale, the senior vice president now owns 115,105 shares in the company, valued at $3,479,624.15. The disclosure for this sale can be found here. Insiders sold 163,676 shares of company stock valued at $5,270,510 in the last 90 days. Insiders own 20.77% of the company’s stock.

Institutional Trading of Dyne Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC raised its position in Dyne Therapeutics by 4.3% in the 2nd quarter. AQR Capital Management LLC now owns 8,495 shares of the company’s stock worth $300,000 after purchasing an additional 352 shares during the period. Nisa Investment Advisors LLC raised its position in Dyne Therapeutics by 904.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after purchasing an additional 669 shares during the period. Amalgamated Bank raised its position in Dyne Therapeutics by 39.9% in the 2nd quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock worth $99,000 after purchasing an additional 796 shares during the period. Principal Financial Group Inc. raised its position in Dyne Therapeutics by 5.9% in the 1st quarter. Principal Financial Group Inc. now owns 15,403 shares of the company’s stock worth $437,000 after purchasing an additional 857 shares during the period. Finally, Wetzel Investment Advisors Inc. purchased a new position in shares of Dyne Therapeutics during the first quarter worth approximately $28,000. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.